Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.

Epidemiology multiple sclerosis second-line treatment treatment response

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
02 2023
Historique:
pubmed: 15 12 2022
medline: 15 2 2023
entrez: 14 12 2022
Statut: ppublish

Résumé

In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression. We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy. Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs). From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09-0.22) for the waiting group and 0.40 (95% CI 0.32-0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30-0.46) and 0.44 (95% CI 0.37-0.52), respectively. By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.

Sections du résumé

BACKGROUND
In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression.
OBJECTIVE
We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy.
METHODS
Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs).
RESULTS
From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09-0.22) for the waiting group and 0.40 (95% CI 0.32-0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30-0.46) and 0.44 (95% CI 0.37-0.52), respectively.
CONCLUSIONS
By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.

Identifiants

pubmed: 36515394
doi: 10.1177/13524585221139156
doi:

Substances chimiques

Immunologic Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

236-247

Auteurs

Camille Sabathé (C)

Université de Nantes, Université de Tours, Inserm, UMR1246 Sphere, Nantes, France.

Romain Casey (R)

Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France/Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Lyon, France/Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, France/EUGENE DEVIC EDMUS Foundation against Multiple Sclerosis, State-Approved Foundation, Lyon, France.

Sandra Vukusic (S)

Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Lyon, France/Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, France/Faculté de médecine Lyon Est, Université Claude Bernard Lyon 1, Lyon, France.

Emmanuelle Leray (E)

EHESP, Université de Rennes, Rennes, France.

Guillaume Mathey (G)

Department of Neurology, Nancy University Hospital, Hôpital Central, Service de Neurologie, Nancy, France/Université de Lorraine, Nancy, France.

Jérôme De Sèze (J)

Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France.

Jonathan Ciron (J)

Department of Neurology, Hôpital Pierre-Paul Riquet, CHU de Toulouse, Toulouse, France.

Sandrine Wiertlewski (S)

Université de Nantes, Nantes, France/Service de Neurologie, Centre de Ressources et de Compétences Sclérose en Plaques, Centre Hospitalier Universitaire de Nantes, Nantes, France.

Aurélie Ruet (A)

University of Bordeaux, Bordeaux, France/Department of Neurology, CHU de Bordeaux, Bordeaux, France.

Jean Pelletier (J)

Aix Marseille University, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France.

Hélène Zéphir (H)

University of Lille, Lille, France.

Laure Michel (L)

Clinical Neuroscience Centre, Rennes University Hospital, Rennes, France/Microenvironment, Cell Differentiation, Immunology and Cancer Unit, Rennes, France/Neurology Department, Rennes University Hospital, Rennes, France.

Christine Lebrun-Frenay (C)

Service de neurologie, CRCSEP, CHU de Nice, UR2CA-URRIS, Nice, France.

Xavier Moisset (X)

Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand, France.

Eric Thouvenot (E)

Department of Neurology, Nimes University Hospital, Nimes, France/Institut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France.

Jean-Philippe Camdessanché (JP)

Department of Neurology, Hôpital Nord, CHU de Saint-Étienne, Saint-Étienne, France.

Serge Bakchine (S)

CHU de Reims, Reims, France.

Bruno Stankoff (B)

Sorbonne Universités, Brain and Spine Institute, ICM, Hôpital de la Pitié Salpêtrière, Paris, France/Department of Neurology, AP-HP, Saint-Antoine Hospital, Paris, France.

Abdullatif Al Khedr (A)

Department of Neurology, CHU d'Amiens, Amiens, France.

Philippe Cabre (P)

Department of Neurology, CHU de la Martinique, Fort-de-France, France.

Elisabeth Maillart (E)

Département de Neurologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France/Centre de Ressources et de Compétences SEP, Paris, France.

Eric Berger (E)

Service de Neurologie Besançon, CHU de Besançon, Besançon, France.

Olivier Heinzlef (O)

Department of Neurology, Hôpital de Poissy, Poissy, France.

Karolina Hankiewicz (K)

Department of Neurology, Centre Hospitalier de Saint-Denis, Hôpital Pierre Delafontaine, Saint-Denis, France.

Thibault Moreau (T)

Department of Neurology, CHU de Dijon, Dijon, France.

Olivier Gout (O)

Department of Neurology, Fondation Rothschild, Paris, France.

Bertrand Bourre (B)

Rouen University Hospital, Rouen, France.

Abir Wahab (A)

Department of Neurology, AP-HP, Hôpital Henri Mondor, Créteil, France.

Pierre Labauge (P)

CRC SEP, Montpellier University Hospital, INSERM, Université de Montpellier, Montpellier, France.

Alexis Montcuquet (A)

Department of Neurology, Hôpital Dupuytren, CHU de Limoges, Limoges, France.

Gilles Defer (G)

CHU de Caen, MS Expert Centre, Department of Neurology, Normandy University, Caen, France.

Aude Maurousset (A)

CRC SEP and Department of Neurology, Hôpital Bretonneau, CHU de Tours, Tours, France.

Nicolas Maubeuge (N)

Department of Neurology, Hôpital Jean Bernard, CHU La Milétrie, Poitiers, France.

Dalia Dimitri Boulos (D)

Department of Neurology, CHU Bicêtre, Le Kremlin-Bicêtre, France.

Haïfa Ben Nasr (H)

Department of Neurology, Hôpital Sud Francilien, Corbeil-Essonnes, France.

Chantal Nifle (C)

Department of Neurology, Hopital Andre Mignot, Le Chesnay, France.

Olivier Casez (O)

Department of Neurology, CHU Grenoble Alpes, Grenoble, France.

David-Axel Laplaud (DA)

Université de Nantes, Nantes, France/Service de Neurologie, Centre de Ressources et de Compétences Sclérose en Plaques, Centre Hospitalier Universitaire de Nantes, Nantes, France.

Yohann Foucher (Y)

Yohann Foucher CIC 1402, CHU de Poitiers, Université de Poitiers, Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH